M 5717 - Merck

Drug Profile

M 5717 - Merck

Alternative Names: DDD107498; DDD498; MMV121

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medicines for Malaria Venture; University of Dundee
  • Developer Medicines for Malaria Venture; Merck Serono; University of Dundee
  • Class Antimalarials; Small molecules
  • Mechanism of Action Peptide elongation factor 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Malaria

Most Recent Events

  • 15 Sep 2017 Phase-I clinical trials in Malaria (In volunteers) in Australia (PO) (NCT03261401)
  • 01 Apr 2015 DDD 498 licensed to Merck Serono worldwide for the treatment of Malaria
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top